Waystar Holding Corp. Q1 2026 Earnings Call Summary

Moby Intelligence

3 min read

Performance was driven by a strategic shift from point solutions to platform evaluations, with win rates exceeding historical averages as providers seek to consolidate vendors.
Management is pivoting the company’s focus from task-level automation toward Agentic workflows, aiming to capture a portion of the $100 billion annual revenue cycle labor market.
The Iodine integration is ahead of plan, bridging the gap between clinical and financial data to address siloed systems that currently lack visibility into payer outcomes.
Revenue growth of 22% was supported by durable core drivers and a net revenue retention rate of approximately 111%, reflecting sticky, mission-critical infrastructure relationships.
The platform’s AI advantage is anchored in 7.5 billion annual transactions and clinical data from approximately 1/3 of U.S. hospital discharges, enabling models to learn ‘why’ denials occur.
Operational discipline and a shift toward higher-margin provider solutions resulted in an adjusted EBITDA margin of 43%, despite macro-related pressures on patient volumes.
Management highlighted that 40% of new bookings in Q1 were driven by AI-powered capabilities, signaling a market preference for prevention and automation over downstream rework.

Full-year 2026 guidance assumes normalized organic revenue growth of approximately 10%, consistent with long-term low double-digit targets.
Management expects the elevated implementation backlog and record qualified sales pipeline to provide growth upside in late 2026 and 2027.
The 2026 seasonality curve for patient payments is expected to show less variability than prior years due to the accelerated shift from print to digital statements.
Strategic priorities include embedding AI deeper into every workflow and driving cross-sell adoption across the installed base to widen competitive advantages.
The company maintains a target leverage ratio at or below 3x, supported by a historical ability to delever by approximately one turn annually.

Patient payment volumes faced near-term pressure from macro dynamics, weather-related impacts, and changes in healthcare coverage during the quarter.
An accelerated conversion from print to digital patient statements created a unit economic headwind for volume-based revenue, though management views this as margin-neutral long-term.
Payer recoupments are growing at more than 2x the rate of overall claim volume, creating significant cash flow volatility for providers that Waystar’s new SKU aims to mitigate.
The company noted that larger contracts (over $1 million annual value) have longer lead times to revenue, typically ranging from 6 to 18 months for full realization.